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Non Standard Abbreviations 
DM   Degenerative Myelopathy 
FACS   Fluorescence-activated Cell Sorting 
fALS   Familial Amyotrophic Lateral Sclerosis 
HEK Cells  Human Embryonic Kidney Cells 
Mut-D   Mutant dog K40 SOD1 
Mut-H   Mutant horse E40 SOD1 
RLN   Recurrent Laryngeal Neuropathy 
ROS   Reactive Oxygen Species 
SOD1   Superoxide Dismutase 1 
WTD   Wild type dog E40 SOD1 
WTH   Wild type horse K40 SOD1 





A glutamic acid to lysine (E40K) residue substitution in superoxide dismutase 1 (SOD1) is 
associated with canine Degenerative Myelopathy: the only naturally occurring large animal 
model of Amyotrophic Lateral Sclerosis (ALS). The E40 residue is highly conserved across 
mammals, except the horse, which naturally carries the (dog mutant) K40 residue. Here we 
hypothesised that in vitro expression of mutant dog SOD1 would recapitulate features of human 
ALS (i.e. SOD1 protein aggregation, reduced cell viability, perturbations in mitochondrial 
morphology and membrane potential, reduced ATP production and increased superoxide ion 
levels) and that horses naturally carry an allele that makes them overly susceptible to 
neurodegenerative diseases.  
As in human ALS, expression of mutant dog SOD1 was associated with statistically-significant 
increased cytoplasmic aggregate formation, raised superoxide ion levels (ROS) and altered 
mitochondrial morphology (increased length and branching (form factor)), when compared to 
wild-type dog SOD1-expressing cells (p<0.05). Similar deficits were not detected in cells 
expressing the equivalent horse SOD1 variant. Our data helps explain the ALS-associated 
cellular phenotype of dogs expressing the mutant SOD1 protein and reveals that species-specific 
sequence conservation does not necessarily predict pathogenicity.  The work improves 
understanding of the aetiopathogenesis of dog canine Degenerative Myelopathy. 
 






For over 20 years, scientists have known that mutations within the gene encoding superoxide 
dismutase 1 (SOD1) enzyme cause some familial forms of the human neurodegenerative 
disease, Amyotrophic Lateral Sclerosis (fALS) [1, 2]. SOD1 mutations were not known to be 
associated with any other naturally-occurring neurological diseases in mammals until 2009, 
when Awano et al. identified a significant association between a missense mutation in SOD1 – 
the substitution of a glutamic acid residue for a lysine residue at the 40th codon (E40K) – and 
the development of Degenerative Myelopathy (DM), an ALS-like disease of dogs [3]. Affected 
dogs are now used as a large animal model of ALS [4] since both ALS and DM share a key 
disease feature: the degeneration of long motor neurons [4, 5]. A protein’s ability to cause 
disease can solely rest with expression of the mutant protein (complete penetrance) or its 
pathogenesis can be modified by other genetic or environmental factors [6]. The dog DM-
associated SOD1 E40K mutation has autosomal recessive inheritance with incomplete 
penetrance [3]: variants in the SP110 gene, as well as aging, are the most important risk factors 
for disease development [7]. This means that dog E40K mutant SOD1, and other genetic 
variants contribute to the DM phenotype.  
 
Horse SOD1 shares 75% amino acid identity to that of dogs, but notably, the lysine residue of 
mutant DM dogs occurs naturally in horses [8]; in contrast, in the vast majority of mammals 
sequenced (within the Ensembl database), the glutamic acid residue is conserved. Our pilot work 
(not shown) confirmed that the horse lysine residue at the 40th codon in SOD1, can be traced 
back at least as far as an ancestral horse genome derived from an animal from the middle of the 
Pleistocene age (4-4.5 million years ago) [9]. However, as ALS-like diseases, such as Equine 
Motor Neuron Disease and long motor nerve degeneration (e.g. as seen in Recurrent Laryngeal 
Neuropathy (RLN)) occur in horses - some with high prevalence [10, 11] - it seems reasonable 
to speculate that wild-type K40 horse SOD1 could predispose these animals to 
neurodegenerative diseases. Indeed, recent evolutionary pressures, such as domestication 
(2000-5000 years ago [12]) or modern management (such as lack of antioxidant provision [13]) 
- perhaps in combination with genetic modifiers - might contribute or be necessary for disease 
onset. Similar domestication and modern management-associated disease exacerbation occurs 
in another highly prevalent equine genetic neuromuscular disease [14-16]. If true for horse 
SOD1, this would shed significant light on the role that the enzyme and its associated pathways 
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play in mammalian neurophysiology and highlight the interaction between evolutionary biology 
and the modern environment and domestication. 
 
The main function of SOD1 is to catalyse the first stage of the neutralisation of superoxide free 
radicals (O2-) into hydrogen peroxide and molecular oxygen [1, 17, 18]; however, the 
mechanisms behind motor neuron degeneration in mutant animals have not been fully 
elucidated. Despite this, most authors agree that the neurodegeneration results from a toxic gain-
of-function, rather than to a loss of enzymatic activity [19, 20]. The most common pathological 
feature reported with ALS- and DM-associated SOD1 mutations is aggregation of the mutant 
SOD1 protein, but these aggregates occur late in the disease course, so there is speculation over 
whether soluble toxic oligomers might convey earlier disease pathogenicity [1, 3]. A recent 
paper highlighted the importance of the residue at the 40th codon (and its molecular bonds with 
91st codon) in human SOD1 in determining the correct structure of the enzyme, as substitution 
of the wild‐type glutamic acid (E) residue to certain residues (aspartate (D), glycine (G), or 
valine (V)) introduced steric hindrance within the β‐barrel plug, and increased protein 
accumulation [21]. Crisp et al. investigated the possible biochemical differences between the 
wild-type and mutant dog SOD1 revealing that the mutant enzyme has a greater propensity to 
aggregate, compared to the wild-type protein in vitro. These authors also reported normal 
enzymatic activity and dimerization of the mutant dog enzyme (SOD1 exists as a homodimer) 
likely because the 40th codon, (in Greek Key loop 3), is remote from the active site, metalation 
sites and structural dimerization bonds [3, 22]. Other common cellular perturbations seen in 
ALS-models include mitochondrial dysfunction and increased oxidative stress [23-25] but these 
(to date) have not been examined for the dog SOD1 mutation. Consequently, further details of 
the pathogenesis associated with the K40 mutation in dog SOD1 remain unknown, which limits 
appreciation of its importance as a naturally occurring ALS model. 
 
The principal aim of our work was to investigate cellular perturbations associated with 
expression of the dog K40 SOD1 protein, and that similar perturbations may be seen with 





Materials and Methods 
 
SOD1 Genotyping in Different Perissodactyla Species and Horse Breeds  
The Perissodactyla order contains 3 families: Equidae (including horse, zebra, donkey and ass), 
Rhinocerotidae and Tapiridae [158]. Exon 2 of SOD1 was amplified from DNA extracted from 
residual EDTA blood samples from different horse breeds (obtained with owner consent), 
Donkey (obtained from the Donkey Sanctuary), Przewalski’s horse, Chapman’s zebra, Onager 
and Malaysian Tapir (latterly all kindly provided by the London Zoological Society). Briefly, 
DNA was extracted from blood samples and amplified using a PCR reaction with species-
specific primers, as described below (see Supplementary Table A), gel extracted and Sanger 
sequenced.  
 
Plasmid Vectors  
Dog and horse cDNA SOD1 cassettes were produced by PCR amplification of cDNA generated 
from mRNA derived from muscle, ensuring amplification of the initiation Kozak sequence to 
beyond the terminal stop codon in the full coding sequence. Dog cDNA was derived from a dog 
that was heterozygous for the E40K SOD1 mutation. Amplicons were cloned (pCR2.1topo; 
Invitrogen) and dog E40 (WTD) and K40 (Mut-D) and horse K40 (WTH) variants were 
selected. Thereafter, the horse K40 sequence was mutated (by PCR mutagenesis) to generate an 
E40 variant (Mut-H) (primer sequences listed in Supplementary A). All sequences were verified 
by Sanger sequencing. Each of the 2 variants, for each species were then cloned into a pLVX-
EF1α-IRES-ZsGreen (Clontech, Saint-Germain-en-Laye, France; 631982), using Clontech In-
Fusion methodology (HD Cloning Kit; Clontech, Saint-Germain-en-Laye, France; 639646). A 
vehicle control was produced that consisted of the plasmid without any SOD1 insert.  
 
Lipofectamine Triple Transfection for Production of Lentiviruses 
Each plasmid was transfected (Lipofectamine 2000, ThermoFisher Scientific, UK; 11668027) 
into HEK-293T cells, alongside 2nd generation packaging (PAX-2 (Addgene, Cambridge MA, 
USA; #35002)), and envelope (pMD2.G (Addgene, Cambridge MA, USA; #12259)) plasmids 
to produce lentiviral particles that were subsequently harvested [26]. The lentiviral particles 
were then resuspended in phosphate buffered saline (PBS) and the number of viral particles 
present per millilitre (transducing units per ml (TU/ml)) determined. Briefly, increasing 
dilutions of lentiviral particles were applied to HEK-293T cells, incubated for 24 hours and, 
using Fluorescent Analysis Cell Sorting (flow cytometry), GFP positive cells counted. A control 
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well was included for each different lentivirus, which was left untreated. Typically yields of 
1x108 TU/ml were achieved. 
 
Cells analysed using a flow cytometer (FACS; BD FCSCanto), were gated according to forward 
and side scatter and 525nm and 575nm (red) when excited at 488nm. Cells were gated according 
to forward scatter and side scatter. A minimum of 10000 cells was counted per replicate per 
condition for each well for all experiments. Where it was necessary simultaneously to evaluate 
both the green and red fluorescence of individual cells, fluorescence compensation was used. 
Compensation settings remained constant throughout the entire experiment. 
 
Cell Types and Cell Culture Conditions 
Either HEK-293T cells (mitochondrial assays) or SHSY5Y cells (aggregation and viability 
assays) were used. Both cells were obtained from the European Collection of Cell Cultures 
(HEK-293T Catalogue Number 05030204 and SHSY5Y Catalogue number 94030304). All 
cells were incubated in Dulbecco’s modified Eagle media (DMEM; Sigma, UK #D5546), with 
10% heat-inactivated foetal calf serum (FCS) and 2mM (1%) L-glutamine and 1% penicillin 
(10IU/ml)/streptomycin (100μg/ml) (maintenance media) for 24 hours at 37°C 5% CO2, before 
being virally transduced with appropriate vehicle and untreated control wells. Viruses were 
added at a multiplicity of infection (MOI) of 20, and incubated for another 48 hours.  
 
Transgene Expression 
Following lentiviral transduction, expression of the different SOD1 variants at mRNA 
(SHSY5Y cells, n=3) and protein levels (HEK-293T and SHSY5Y cells, n=3), was performed 
by quantitative real-time PCR (qPCR) and western blot. Cells seeded at 100,000 cells per well 
in a 6 well plate, were cultured for 24 hours in maintenance media before adding lentiviruses 
expressing each of the 4 SOD1 variants and the empty (vehicle) vector to wells. One control 
well was left untreated. After 72 hours all RNA and proteins were extracted. The mRNA was 
extracted using RNA-Bee reagent (Amsbio) according to the manufacturer’s protocol (with 
inclusion of an additional 1:1 chloroform extraction following phase separation, and inclusion 
of glycogen at 10μg/ml during precipitation to maximise RNA yield). Proteins were solubilised 
in 250μl of chilled radioimmunoprecipitation assay buffer (RIPA) (50mM Tris pH 7.5, 150mM 
NaCl, 1% NP40, 0.5% NaDeoxychlorate, 0.5% SDS, 1mM EDTA, 1mM EGTA, 1mM PMSF 
and 1x protease inhibitor), and cellular debris pelleted. Soluble proteins within the supernatant 
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were removed and quantified against known bovine serum albumin protein standards (BioRad 
DC Protein Assay, UK).  
 
Equal protein sample concentrations were boiled, with a loading buffer, for 5 minutes, and 
proteins separated on a commercially-available precast polyacrylamide gel (Any kD Mini-
PROTEAN TGX Stain-Free Gel, BioRad, UK; 4568123S) (100V for 90 minutes) and 
transferred (300mA for 90 minutes) to a PVDF blotting membrane (Amersham Hybond P, GE 
Healthcare Life Sciences. UK; RPN303D). Membranes were blocked in PBS with 0.05% Tween 
containing 10% milk powder for 1 hour at room temperature followed by incubation with an 
anti-SOD1 antibody (FL-154, sc-11407; Santa Cruz Animal Health at 1:1000) and an anti-beta-
tubulin antibody (as a loading control) (ab6046, Abcam, UK, at 1:10000), in PBS with 0.05% 
Tween containing 5% milk overnight, at 4°C. Following 3 washes, secondary goat anti-rabbit-
IgG horseradish peroxidase-linked whole antibody (Dako, UK; #D0487 at 1:5000) in PBS-
0.05% Tween was added and incubated for 1 hour at room temperature, whilst shaking. Blots 
were developed with Amersham ECL Prime Western Blotting Detection reagent (GE 
Healthcare, UK; #RPN2232) and visualised on a Kodak developer. Blots were run on all 
biological replicates.  
 
Quantitative PCR  
All samples for comparison by qRT-PCR were processed together. qRT-PCR assays were 
designed to amplify species-specific regions of SOD1, including human, dog and horse to allow 
for quantification of their total expression in comparison with 3 housekeeping genes. These 3 
housekeeping genes were GAPDH, POLR2F and MPRIP which have stable expression in 
SHSY5Y cells [27]. RNA quantity and purity were confirmed by Nanodrop analysis (ND1000, 
Thermo Scientific). A cDNA library was synthesised from the isolated RNA using the Precision 
nanoScript2 Reverse Transcriptase kit (Primerdesign). Random nonamer and oligo-dT priming 
were both used during this cDNA synthesis stage with 1.6μg of total RNA per 20μl reaction. 
Following synthesis, cDNA samples were diluted (1:10) with RNAse/DNAse-free water, giving 
a final cDNA concentration of approximately 4ng/μl (assuming 1:1 conversion of RNA to 
cDNA). 
 
qPCR reactions were performed in triplicate with 2μl cDNA per well (approximately 8ng), using 
PrecisionPLUS SYBR green Mastermix (Primerdesign). The primers were used 
(Supplementary Data A) at a final concentration of 500nM. Primers for the housekeeping genes 
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were sourced from Hoerndli FJ et al. 2004 [27]. Reactions were run on a real-time-PCR light 
cycler (CFX384 light cycler; BioRad), in black 96-well plates, with clear caps 
(ThermoScientific). All runs included melt curve analysis and template-free controls. All primer 
pairs produced single amplicons and reactions were of comparable efficiency (95-100%) as 
established by standard dilution curves and analysis of individual traces. The qPCR cycle used 
was as previously reported [28, 29]. Quantification cycle (Cq) values were determined by 
regression analysis of the amplification traces. Average Cq values for each replicate reaction 
were used directly before analysis (Normfinder, geNorm). Samples exhibiting more than 10-
fold deviation in relative expression from the dataset average in a majority of genes were 
typically excluded from analysis. Experimental normalisations using suitable candidates used 
the linearised expression data of the respective genes, or where multiple normalisation genes 
were used, the geometric average of the linearised expression data. 
 
Aggregation Studies 
Cells were seeded onto glass coverslips pre-treated with Matrigel (BD Matrigel, BD 
Biosciences, UK; 1:10) at a density of 50000 cells per coverslip in 24 well plates. Cells on 
coverslips were infected in triplicate, on 3 different occasions (n=9). Forty-eight hours after 
transduction all coverslips were washed with PBS, fixed (4% paraformaldehyde (PFA)/0.1% 
triton; 4°C for 20min, followed by 8% PFA; 30min at room temperature) and stained with a 
nuclear marker, Hoechst (Life Technologies, UK; at 1:5000, in PBS). All cells were 
immunolabelled for SOD1 (0.1% triton in PBS for 30 minutes at room temperature, wash step, 
using an anti-SOD1 antibody (FL-154, Santa Cruz) 1:100 in PBS for 1 hour at room 
temperature, wash step, and lastly addition of a secondary antibody bound to the AlexaFluor 
594, 1:500, 1 hour at room temperature). The coverslips were mounted onto glass slides using 
Hydromount (National Diagnostics, UK; HS106). Each slide, containing all replicates from one 
condition, was examined with the investigator blinded to the condition, using fluorescence 
microscopy, and 10-15 random images were captured (using 40x objective) per coverslip. The 
total number of transduced (green) cells was recorded per image, and of these, the total number 
of cells containing cytoplasmic, nuclear or cytoplasmic and nuclear aggregates recorded. 
Aggregates were defined as intense accumulations of red colouration either within the 
cytoplasm or nucleus of a cell [19]. The results per image were summated for each of the 9 




SHSY5Y cells were plated at a density of 50000 cells per well in maintenance media and viral 
transduction performed after 24 hours. After another 48 hours H2O2, at concentrations ranging 
from 0, 200, 400, 600, 800 and 1000μM in maintenance media, were added to each condition, 
in triplicate. The cells were incubated in H2O2 for exactly 24 hours before being trypsinised, 
pelleted, washed in PBS and stored on ice for no longer than 30 minutes. Any floating cells 
were collected and added to the trypsinised cells before pelleting. To quantify how many cells 
had died, the cell pellets were resuspended in propidium iodide (1mg/ml in water; Sigma-
Aldrich, Gillingham, Dorset UK) (1:500 dilution in PBS), incubated for 1 minute, at room 
temperature in the dark and then the number of red cells were recorded by flow cytometry. 
Untreated control cells set the background redness levels.  
 
Mitochondrial Assays 
Mitochondrial Morphology and Volume 
HEK-293T cells were seeded at a density of 25000 cells per chamber in a 35mm glass-bottomed, 
imaging dish with 4 compartments (u-Dish 35mm Quad ibiTreat, ibidi, Germany). Each 
condition had 4 replicates. Forty-eight hours after viral transduction the media was removed, 
and the cells incubated at 37°C for 30-45 minutes with 250μl of recording media (125mM NaCl, 
5mM KCl, 1mM NaH2PO4, 20mM HEPES, 5.5mM D+ glucose, 5mM NaHCO3, 1mM CaCl2, 
pH 7.4) containing 50nM MitoTracker Red FM (Molecular ProbesTM, Thermo Fisher 
Scientific, M22425). Five minutes before imaging, 1μl of the nuclear marker Hoechst 33342 
was added to the well. Control cells were incubated with magnesium green (Thermo Fisher 
Scientific, M3733) (4μM in the recording media, containing the MitoTracker Red). Z-stacks 
were acquired using a Leica SP5 confocal microscope (63X objective) on a randomly-selected 
region of >10 transduced cells. The number of slices and step size were kept constant, and the 
microscope detection settings were fixed.  
 
The shape descriptors aspect ratio (AR) and form factor (FF) were evaluated as measures of 
mitochondrial elongation and branching, respectively. The z-stacks were imported into ImageJ 
(Fiji; [30]). Here, the image within the z-stack that was most representative of the mitochondrial 
network in a transduced cell was selected, and thresholding performed (settings were kept 
constant across all replicates). The cell was highlighted and the AR and FF (1/circularity) 
calculated. This was repeated for every transduced cell imaged (minimum of 10 cells per 
replicate, four replicates per condition). 
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To assess mitochondrial volume, analysis was performed using the Volocity software, where a 
custom package was designed to allow for the calculation of the cytosolic volume (green), the 
nuclear volume (blue) and the mitochondrial volume (red).  
 
Mitochondrial Membrane Potential (Δψm) 
Confocal Microscopy: Experimental conditions were set up as described above for the 
mitochondrial morphology and volume experiments. Continuous monitoring of Δψm was 
achieved by loading HEK 293T cells with the fluorescent potentiometric dye TMRM (Sigma, 
T5428). A non-quenching concentration of TMRM (50nM) in recording media supplemented 
with 10μM verapamil hydrochloride (Sigma, V4629) was added to all wells. The cells were 
incubated for 30 minutes at 37°C. Real-time imaging was performed on a temperature-
controlled (37°C) Leica SP5 confocal microscope (40X objective). Time series were acquired 
and the mitochondrial TMRM fluorescence decay was monitored in real-time, until a plateau 
was reached. At this point, directional dye behaviour was confirmed by adding 20nM carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP; Sigma Aldrich C2920). Time series 
were analysed using ImageJ (Fiji; [30]). Settings were kept constant throughout all experiments.  
 
Flow Cytometry: HEK-293T cells were seeded at a density of 25000 cells per well in a 24 well 
plate and incubated in maintenance media for 24 hours, at 37°C 5% CO2, followed by viral 
transduction. Cells were trypsinised, the cell suspensions pelleted by centrifugation and the 
supernatant discarded. The cells were then resuspended in recording media containing 50nM 
TMRM and incubated for 30 minutes at 37°C, before they were repelleted by centrifugation and 
the supernatant replaced with PBS. The cell pellets were kept in the dark on ice, for no more 
than 30 minutes, while the red intensity of transduced cells was recorded using a flow cytometer. 
Correct directional dye behaviour for TMRM was confirmed for all conditions (vehicle, WTD, 
Mut-D, WTH and Mut-H) and control cells (non-virally transduced cells) using 20nM FCCP. 
Each condition was plated out in triplicate and this experiment was repeated on three occasions: 
(i.e. n=9 per condition). 
 
ATP production 
ATP production was measured across all conditions and untreated HEK-293T control cells, 
using a commercially-available colourimetric assay (ATP Assay Kit 
(Colourimetric/Fluorometric), Abcam, ab83355). Transduction efficiencies were confirmed to 
be >97% (via flow cytometry) for all conditions. HEK-293T cells were plated out at 500000 
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cells per well (6-well plate), and virally transduced. Four replicates were included per condition. 
Forty-eight hours after transduction the cells were trypsinised and counted using a 
haemocytometer. All cell suspensions were diluted to 500000 cells per 50μl with an ATP Assay 
Buffer (supplied with the kit). ATP concentrations were determined according to the 
manufacturer’s protocol, in duplicate, with appropriate background controls included per 
replicate. A standard curve from known ATP concentrations (0-10nmol) was included for each 
plate that was read. The optical density at 570nm was read using a microplate reader 
(SpectraMax L Luminescence Microplate Reader, Molecular Devices). All duplicate readings 
were averaged (for standards and samples), and the background control readings subtracted. The 




Flow cytometry was utilised to measure the red fluorescence of the virally-transduced cells 
when treated with the MitoSOX™ Red reagent (Thermo Fisher Scientific, M36008). HEK-
293T cells were plated out at 50000 cells per well, in a 24 well plate. Conditions were set up in 
triplicate, and the experiment was repeated on 3 separate days (n=9 total). Forty-eight hours 
after viral transduction, wells were washed with PBS, trypsinised, the cells pelleted and stored 
on ice for no more than 30 minutes. Cells were resuspended in 5μM MitoSOX Red in PBS and 
incubated at 37°C for 10 minutes. Red fluorescence intensities were assessed in a minimum of 
10000 virally-transduced cells per replicate, per condition, via flow cytometry. The median red 
fluorescence intensity was averaged across each replicate per condition as a measure of the 




The change in the net charge, at physiological pH, between the wild-type and mutant forms of 




Continuous data were analysed with either a one-way (aggregation) or two-way (viability) 
ANOVA and post-hoc testing consisted of Tukey’s multiple comparison test. Differences were 
considered statistically significant when p<0.05. To account for the effects of replicate 
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(mitochondrial morphology and membrane potential (confocal microscopy)) or day 
(mitochondrial membrane potential (FACS), ATP and superoxide levels) on the results 
achieved, linear regression using the following equation was used: outcome ~ SOD1 genotype 
+ effect (i.e. day or replicate). Post-hoc testing (Tukey’s multiple comparisons test) was 
performed to assess if there were any statistically significant differences (p<0.05) in the 




Perissodactylae SOD1 Genotype 
Sequencing of the equid species (including 7 different horse breeds (Supplementary Data B), 
donkey, zebra, onager and Przewalski’s horse) and the Tapiridae (Malaysian Tapir) revealed 
conservation of the lysine (K) residue in all these species. In contrast, the onager was 




Successful transduction of all 4 SOD1 variants was confirmed by western blot analysis. The 
WTH and Mut-H SOD1 protein levels were consistently comparable in both HEK-293T and 
SHSY5Y cells (Figure 3B), however the WTD protein levels were consistently double those of 
the Mut-D SOD1 protein (Figure 3a). Correspondingly, the relative mRNA expression of WTD 
SOD1 was confirmed by qPCR, to be approximately double that of the Mut-D (p<0.0001) 
(Figure 3c), conversely no difference in the mRNA expression level of the WTH and Mut‐H 
SOD1 was identified (P > .05) (Supplementary Figure 3).  
 
Aggregation 
Aggregation of mutant SOD1 proteins is a hallmark of both SOD1-associated human and canine 
diseases: ALS and DM [1, 31]. However, neither horse SOD1 variant showed an increased 
propensity to aggregate; conversely, as expected, the mean percentage of cells expressing the 
Mut-D SOD1 that contained cytoplasmic aggregates was significantly higher than the mean 
percentage of cytoplasmic aggregates in cells expressing all other SOD1 variants, and control 




Increases in cellular hydrogen peroxide will trigger cell death by apoptosis, once a threshold 
level is reached. We hypothesized that cells expressing either K40 SOD1 variants would be 
more susceptible to H2O2-induced cell death compared to their E40 counterparts. This 
hypothesis was rejected: cells expressing WTH or Mut-H SOD1 showed no significant 
differences in H2O2-induced cell death over the range of H2O2 concentrations applied (0-
1000μM). Cells expressing WTD SOD1 had similar susceptibility to H2O2-induced cell death 
as cells expressing Mut-D SOD1 over the entire range of H2O2 concentrations applied (0-
1000μM) (p>0.05) (Figure 5 A-F).  
 
Mitochondrial Morphology 
A cell’s mitochondrial network is a complex, often highly branched system kept in a careful 
balance between fission and fusion. Imbalances in their morphology can reflect impaired 
functionality and are reported in ALS-models [25]. There were no differences in the morphology 
of the mitochondrial networks in cells expressing the WTH and Mut-H SOD1 variants and there 
were no statistically significant differences between the cells expressing the dog SOD1 variants 
evaluating the Aspect Ratio. However, the form factor (branching) was significantly greater in 
cells expressing the Mut-D SOD1 protein compared to cells expressing the wild-type dog SOD1 
(p<0.05) (Figure 6). There were no significant differences noted between the mitochondrial 
volumes of transduced HEK-293T cells under any of the conditions (control, vehicle or SOD1 
variants) (p>0.05) (Supplementary Figure 2). 
 
Mitochondrial Membrane Potential  
As recommended by Perry et al. 2011, two methods were used for measurement of the ΔΨm 
[33]. However, there were no statistically significant differences in the ΔΨm between any of 
the SOD1 variants, identified using confocal microscopy (Figure 7A) or flow cytometry (Figure 
7B). Cells expressing the mutant dog SOD1 (5028+6716) produced significantly greater levels 
of superoxide ions compared to all other SOD1 variants and controls (control 373.6+168.4 
p=0.0008, vehicle 427.2+252.5 p=0.0009, WTD 870.2+950.5 p=0.002 WTH 1784+1629 
p=0.016 and Mut-H 1362+521.5 p=0.012), however no ΔΨm (either measured with flow 
cytometry or confocal microscopy) (or ATP level differences) were seen between them and the 




The mean ATP concentrations (nmol/5x105 cells) were lower for the K40 SOD1 variants for 
both dog and horse, with the Mut-H-SOD1-expressing cells having a statistically significant 
higher mean ATP concentration than the 2 K40 SOD1 variants (p<0.05) (Figure 7C).  
 
Superoxide Ion Concentrations 
Superoxide ions are mainly produced by complex I and III of the electron transport chain and 
are deposited in the intermembrane space within mitochondria [34]. Elevations of these reactive 
oxygen species (ROS) are a common feature of different ALS-causing SOD1 mutations and are 
particularly deleterious to many cellular structures and functions [23]. In the cells expressing 
the Mut-D SOD1 variant, the superoxide concentrations were significantly higher than all other 
conditions (P<0.05) (Figure 7D). 
 
Protein Charge 
The substitution of a glutamic acid for a lysine residue in SOD1 was predicted to result in the 
net charge (at pH 7.4), to change by +2 [31]. This would change the overall charge of the dog 
K40 SOD1 to -1.4 (mutant) from -3.4 (wild-type). The overall charge of the wild-type horse 
SOD1 was lower than the charges of the different dog SOD1 variants at -4.2 (and hence the 
mutant horse variant was predicted to have charge, -2.2). 
 
Discussion 
This research was aimed at further investigating the cellular consequences of a mutation in dog 
SOD1 associated with an ALS-like phenotype and examined whether similar perturbations exist 
when associated with the equivalent horse protein. We identified prominent cellular deficits in 
cells expressing dog mutant SOD1 including raised superoxide ion concentrations and altered 
mitochondrial morphology; as such, our work further corroborates the work of Crisp et al. [19], 
and reveals additional functional deficits associated with the dog DM mutation that relate 
closely to those detected in SOD1-associated ALS [23, 25]. In contrast, our work shows that a 
lysine residue at the 40th codon in horse SOD1 does not produce the same pathological 
phenotype in vitro. Previous analysis of the biochemistry of the mutant dog SOD1 protein did 
so using a fluorescent protein-tagged mutant dog SOD1, however fluorescent tagging of SOD1 
proteins can alter their biochemical properties [19, 35, 36]. Instead, here we examined 
aggregation tendency using an untagged approach. Our work confirms that the mutant lysine 
residue at the 40th codon in dog SOD1 background induces protein aggregation.  
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The 40th codon in SOD1 is located between the 3rd and 4th β strands in Greek key loop 3 and 
the pathogenicity of mutations in this region. has recently been speculated to arise from the 
introduction of steric hindrance, caused by opposing charges or side‐chain repulsions, resulting 
in loss of the β‐barrel plug (which maintains hydrophobicity in the core of the SOD1 molecule) 
and thus promoting SOD1 protein misfolding and aggregation [21]. In humans, an E40G 
mutation is reported to be associated with development of fALS [37], however, mutating the 
40th codon to a lysine (K) residue in humans did not increase the human SOD1's propensity to 
aggregate [19], similar to our results for the wild‐type horse SOD1. This implies that other 
residues in the dog SOD1 protein act with the K40 amino acid to produce the mutant dog 
SOD1's deleterious aggregation. This phenomenon has been reported previously 38-40; for 
example, in 1997 the first causative mutation of Parkinson's disease in alpha‐synuclein (A53T) 
was published, in contrast, the mutant residue T53, is the wild‐type residue in rodents.40 
Parkinsonian‐like diseases are not reported to occur spontaneously in rodents [41], suggesting 
that the presence of threonine in rodent alpha‐synuclein is non‐pathogenic in contrast to 
humans. These species specificities might therefore explain the common occurrence of failure 
of artificially generated (predominantly) rodent models to recreate the human phenotype: even 
recently, several devastating mutations within the human α‐sarcoglycan gene, when created in 
the equivalent mouse gene, failed to produce a dystrophic phenotype [38]. Our study therefore 
is an important reminder that protein sequence differences between species can affect a 
missense mutation's pathogenicity. It also supports the use of naturally-occurring 
(spontaneous) animal models (i.e. with pre-identified relevant phenotypes) in disease 
investigation. 
 
The propensity of ALS‐associated SOD1 mutants to aggregate is influenced by several factors 
[21, 42-46] which collectively affect the protein's stability immediately after its biosynthesis; 
decreased stability increases protein aggregation [47]. The protein's charge at a physiological 
pH being more negative can convey a greater stability [47-50]. Thus the more negative charge 
of the horse K40 wild‐type SOD1 (−4.2) (compared to K40 mutant dog SOD1 with an overall 
charge of −1.4) could make it inherently more stable and, presumably therefore, less likely to 
aggregate. Interestingly, in human SOD1 the residue present at the 40th codon is pivotal for 
correct folding of the protein, and as such to resist protein aggregation [21], perhaps by 
maintainance of the hydrophobic center of the enzyme. Although the human K40 SOD1 has 
not been shown to have an increased aggregation potential [19], their G40 (ALS‐causing SOD1 
mutation), D40, and V40 (tagged to YFP) counterparts appear to form increased numbers of 
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fluorescent inclusions in a cell‐based model as well as being predicted in silico to hinder 
appropriate intramolecular bonds [21]. The residue at the 40th codon forms the hydrophobic 
barrier (β‐barrel plug) in partnership with the 91st codon equivalent, being in humans (and dogs) 
typically K(91), whereas in horses it is an E. The latter suggests that in the wild‐type horse 
SOD1 the K40 and E91 have effectively reversed, presumably still producing an efficient β‐
barrel plug. Thus it could seem surprising that the mutant horse SOD1 (E40) protein here did 
not show an increased propensity to aggregate however, the situation is likely more complex, 
probably affected by the surrounding residues as the human K40K91 SOD1 variant also did 
not show an increased aggregation [19]. Future work to investigate if these surrounding 
residues moderate any negative effects the 40th codon residue may have on aggregation, within 
the dog and horse SOD1 proteins seems important. 
 
The lysine residue at the 40th codon is conserved across 5 different species within the 
Perissodactyla order, with the exception of the Onager whereby the individual was 
heterozygous for the lysine (K40) residue and an arginine (R40) residue. We also confirmed 
that the K40 horse SOD1 variant was present in an equine ancestor, 4-4.5 million years ago by 
blasting the SOD1 exon 2 sequence of the modern horse genome to the ancient horse genome 
[9], and it appears that evolutionary pressures have not resulted in the removal of this residue; 
to the best of the author’s knowledge there is no publically available horse genomes where a 
different residue can be found at the 40th codon, and within our laboratory we have identified 
this residue at the 40th codon in over seven different horse breeds (Supplementary Figure 1). 
Such pressures could have included domestication, whereby horses were selectively bred for 
their coat-colour, greater height and lower limb sturdiness [12]; greater height is the principal 
risk factor for the development of RLN in horses (an ALS-like long-motor axonopathy). Indeed 
in dogs, to develop the DM phenotype, advancing age as well as the expression of the K40 
SOD1 protein is typically needed [3], highlighting that the K40 residue might only be 
pathogenic under certain circumstances. Certain circumstances might simply have not 
developed or been applied to horses to allow for manifestation of a pathological phenotype. 
Alternatively, we cannot rule out the possibility that other (as yet unidentified) deficits 
associated with the K40 horse protein, might predispose to neurodegeneration in (for example) 
especially long axons, as seen in equine RLN [11]. 
 
An important pathological feature of ALS-models is higher cellular ROS levels in cells 
expressing mutant SOD1 variants [23]. Superoxide ions (in particular) are highly reactive and 
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severely deleterious to cells, causing damage to DNA and lipid membranes. Thus, the fact that 
superoxide concentrations were significantly higher in cells overexpressing the mutant dog 
SOD1 compared to all other SOD1 variants, and controls, reveals an important feature 
underlying DM in dogs. Possible pathophysiological mechanisms underlying these higher 
superoxide levels include (i) activation of cytochrome c-catalysed oxidation and peroxide 
production causing elevated ROS levels (as seen when mutant G93A human SOD1 
accumulates within the mitochondrial intermembrane space) [51], (ii) complex 1 inhibition (see 
below) and (iii) a reduction in the enzymatic activity of mutant SOD1 proteins. Saccon et al. 
2013 showed that even mutant SOD1 proteins with mutations remote to the protein’s active 
site can have reduced dismutase activity, likely due to disruptions with SOD1 binding to 
important co-factors [20]. An E40K dog SOD1 recombinant protein had normal enzymatic 
activity [19], however the activity of the endogenous mutant protein has not been evaluated. 
Further work is needed fully to tease out the mechanism(s) underlying the elevation in 
superoxide levels seen with K40 dog SOD1 expressing cells; however, our data reveals the 
possible role of treatments aimed at quenching free radicals in treatments of affected dogs (and 
humans with ALS). 
 
Mitochondrial morphological perturbation in cells expressing the mutant dog SOD1 variant 
was revealed in this model: the mean form factor of mutant dog SOD1 expressing cells was 
significantly greater than the mean form factor of wild-type dog SOD1 expressing cells. Form 
factor describes the degree of branching of a cell’s mitochondrial network and when evaluating 
the mitochondrial networks, qualitatively, in cells expressing the mutant dog SOD1 the 
increased form factor appeared to be characterised by an increased interconnectivity of the 
mitochondria (rather than an absolute elongation). This could result from increased fusion of 
neighbouring mitochondrial, coupled with decreased mitophagy. Increased form factor occurs 
in cells expressing mutant Parkin in an in vitro model of Parkinson’s Disease [52], in cells 
transiently treated with rotenone [53] and when cellular ROS levels are elevated [54]. Certain 
Parkin mutations reduce the activity of complex I within the electron transport chain, and as 
rotenone is known to be an inhibitor of complex I [52, 55], it seems reasonable to assume that 
impairment of complex I leads to increased mitochondrial branching. In addition, various 
human mutant SOD1 proteins also reduce the activity of complex 1 [56, 57]. This could suggest 
that the increased form factor seen in cells expressing the mutant dog SOD1 protein results 
from the mutant protein’s interaction with complex 1 and inhibiting its activity. Indeed, this 
inhibition can lead to elevated superoxide levels (as seen here), and reduced ATP production. 
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(ATP levels were lower in cells expressing the mutant dog SOD1 compared to the wild-type 
dog SOD1, although not significantly) [58, 59]. Future work investigating imbalances between 
mitochondrial fusion and fission, and the role of ROS in dog DM and ALS [60] seems 
important. 
 
We found no difference in the inner mitochondrial membrane potential (ΔΨm) of cells 
expressing the different SOD1 variants. However, since mitochondrial dysfunction was 
identified in other ways, it is conceivable that a longer expression time course might be needed 
to fully elucidate the affects of mutant dog SOD1 on ΔΨm (age is an important risk factor in 
ALS and DM) [61]. In contrast, human mutant G93A SOD1 reduces the ΔΨm within 
transfected NSC-34 cells [24], however this is one of the more severe SOD1 mutations 
encountered in human ALS [62]. Certain mitochondrial pathological phenotypes seen with the 
expression of SOD1 mutants only occur in neuronal cell lines [63], thus the measurement of 
the ΔΨm with mutant dog SOD1 expression might have been better investigated in a neuronal 
cell line. Alternatively, given that dog DM is recessive, the mutant proteins might need to be 
expressed on a SOD1-null background to detect ΔΨm defects.  
 
Direct cytotoxicity and increased susceptibility to oxidative stress are both features seen with 
the over-expression of human SOD1 mutants in cell models of ALS [23, 24]. Conversely here 
the proportion of cell death induced by rising H2O2 concentrations was similar between the 
cells expressing the wild-type and mutant dog SOD1 proteins. The difference in cell viability 
is likely explained by several factors: the effect that different cellular backgrounds can have, 
the assay used to estimate viability and, most importantly, how deleterious the particular 
mutation is in vivo. The severity of ALS caused by human mutant SOD1 variants is directly 
associated with their ability to form aggregates [62]. Whilst the K40 mutation in dogs is 
associated with aggregation, aggregation is still relatively low in this model (mean percentage 
of cells containing mutant dog SOD1 aggregates: YFP-tagged mutant dog SOD1: 
approximately 20% [19] and non-tagged: 5.4%+1.8). 
 
Mitochondrial abnormalities were not recorded in any of the assays performed with the wild-
type or mutant horse SOD1 variants, therefore it was surprising to see a significant increase in 
ATP production in cells expressing the mutant horse (E40) SOD1 variant compared to the wild-
type horse (K40) SOD1. Indeed, both species’ K40 SOD1 variants-expressing cells had lower 
mean ATP levels, compared with their E40 SOD1 variant counterparts. Whilst we did not 
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identify ALS-associated cellular perturbations associated with the K40 SOD1 sequence of the 
wild-type horse SOD1, evolutionary change from E40 to K40 that occurred in horses, might 
have been at the expense of cellular ATP production, necessitating other concomitant 
evolutionary changes that now give horses their incredible oxidative capacity [64]. 
 
The validation of protein expression, following viral transduction with the dog SOD1 variants, 
consistently revealed lower mutant protein expression, in both HEK-293T cells and SHSY5Y 
cells. This phenomenon has been reported with dog and human SOD1 mutants in transfection 
and transduction experiments in vitro [23, 35, 62, 63, 65 with most authors commenting that 
the difference is solely explained by insoluble mutant SOD1 protein aggregates not being 
represented on a Western Blot [66]. However, the mRNA expression of various human mutant 
SOD1 have also been shown consistently to be lower than those of the wild-type SOD1 in an 
NSC-34 cell model of ALS [67] revealing other possible mechanisms. Ge et al. 2006 showed 
that mRNA of human mutant SOD1 variants G93A, A4V and G41S decayed at a significantly 
greater rate in transfected cells compared to the wild-type SOD1 variant [67], and this in turn 
was associated with decreased mutant SOD1 protein expression. The increased mutant SOD1 
mRNA degradation, confirmed to be neuronal tissue specific, was accompanied by a loss of 
binding of the mutant mRNA to RNA-binding proteins, though the precise RNA binding 
proteins (there are over 420 known) were not identified [68]. The role of these pathways 
however is emphasised by the identification of implicated proteins in fALS (e.g. TDP-43) [73], 
as unbound RNP complexes can disrupt other cellular pathways [70]. Our data suggest that 
these pathways might also contribute to the dog DM phenotype. 
 
In conclusion, here we thoroughly investigated cellular perturbations associated with a dog 
SOD1 mutation and examined its consequence in horses. Our study supports previous work 
into the pathological features associated with mutant dog SOD1, and importantly, extends this 
work to show that the endogenous (i.e. untagged) mutant dog SOD1 has a greater aggregation 
potential compared to its wild-type counterpart, and causes increased superoxide levels and an 
imbalance in mitochondrial fusion and fission. Further work is needed to fully investigate how 
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Figure 1. Conservation of the 40th codon in SOD1 across different mammalian species. A 
glutamic acid residue (E) is present at the 40th codon (blue) in most mammals with the exception 
of the wild-type horse, armadillo and the mutant SOD1 variant of the dog where a lysine (K) 





Figure 2 Genomic sequencing from five different Perissodactyla species (Horse, Przewalski’s 
horse, Onager, Zebra, Donkey and Tapir), revealed conservation of the lysine residue at the 40th 
codon in all species with the exception of the Onager whereby the animal was heterozygous for 








Figure 3 Western blot of exogenous SOD1 protein expression with the different variants. 
Equivalent protein expression of horse SOD1 variants (wild-type (K40) (WTH) and mutant 
(E40) (Mut-H)) were seen in virally-transduced cells (A). Whilst wild-type (E40) dog SOD1 
mRNA (C) and protein (B) levels were approximately double those of its mutant dog (K40) 
SOD1 counterpart. Representative western blots from virally transduced cells expressing 
different SOD1 variants and blotted for SOD1 and β-tubulin (B-tub: loading control). Human 
and horse SOD1 separate at the same molecular weight (~18kD) whilst dog (dog) SOD1 
(cSOD1) has a molecular weight of approximately 16kD. 
 
A) Key: 1) control cells (no transduction), 2) vehicle alone, 3) wild-type horse (WTH) and 4) 
mutant horse (Mut-H).  
B) Key: A) control cells, (no transduction), B) vehicle alone, C) wild-type dog (WTD) and D) 
mutant dog (Mut-D).  
C) Relative expression of dog SOD1 (WTD (E40) and Mut-D (K40)) mRNA in virally 
transduced SHSY5Y cells, normalised to GADPH, MPRIP and POLR2F expression identified 
with specific primers to dog SOD1. The relative expression of WTD SOD1 was significantly 
greater than its Mut-D SOD1 counterpart (p<0.0001), in virally transduced cells. Negligible 
expression of dog SOD1 was seen in control and vehicle. Data is expressed as the mean + 
standard deviation from experimental replicates (n=3). Bars represent the p-values (solid: 





Figure 4 A, SOD1 immunocytochemistry of control and virally-transduced SHSY5Y cells 
including the vehicle (plasmid alone, no SOD1 insert), wild-type dog (E40) SOD1 (WTD 
SOD1), mutant dog (K40) SOD1 (Mut-D SOD1), wild-type horse (K40) SOD1 (WTH SOD1) 
and mutant horse (E40) SOD1 (Mut-H SOD1). Mutant dog SOD1 aggregates can clearly be 
seen (white arrow) and are noticeably absent from the other conditions. In the merged image 
nuclei fluoresce blue, positively transduced cells green (with the exception of the control cells) 
and SOD1 fluoresce red with immunolabelling. Black scale bar = 20μm. B, Graphical 
representation of the percentage of cells containing cytoplasmic SOD1 positive aggregates 
(identified by immunocytochemistry), with different dog and horse SOD1 variants (mean ± 
standard deviation). The cells expressing the mutant dog SOD1 protein contained significantly 
more cytoplasmic aggregates than compared to the other SOD1 variants and controls (P < .05). 






Figure 5 Susceptibility of SHSY5Y cells to H2O2-induced cell death over a range of H2O2 
concentrations (0-1000μM), expressing different SOD1 variants via viral transduction (wild-
type dog (E40) (WTD), mutant dog (K40) (Mut-D), wild-type horse (K40) (WTH) and mutant 
horse (E40) (Mut-H) SOD1), with control cells and a vehicle control (GFP-only). The mean 
percentage of dead cells (+ standard deviation (error bars)) (as denoted by being propidium 
iodide (PI) positive on flow cytometry) is reported, for each condition, at specific H2O2 
concentrations in panels b-f. P-values from Two-Way ANOVA with post hoc correction 
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Figure 6 A-C: Mitochondrial morphology descriptors (Aspect Ratio and Form Factor) of virally-transduced HEK-293T cells expressing different 
veterinary SOD1 variants (wild-type dog (E40) SOD1 (WTD), mutant dog (K40) SOD1 (Mut-D), wild-type horse (K40) SOD1 (WTH) and mutant 
horse (E40) SOD1 (Mut-H)) with appropriate vehicle and non-virally transduced control cells. The mean + standard deviation of each morphological 
descriptor, per condition, is represented by the horizontal bar and error bars, respectively. The morphology values for each cell (minimum of 10 
cells, 4 wells per condition) are displayed. The solid black bars represent a p<0.05; from a mixed model with post-hoc correction including the well 
number as a co-variant. Cells expressing the mutant dog SOD1 showed a significantly increased form factor (mean+SD: 1.439+0.1565), suggesting 
that the mitochondrial network was longer and more highly branched, compared to the cells expressing the wild-type dog SOD1 (1.356+0.09086) 
(p=0.00507). D: This can be appreciated in the representative confocal images of cells expressing wild-type dog SOD1 (WTD SOD1) or mutant 
dog SOD1 showing greater branching of the mitochondrial network (MitoTracker® Red) in the mutant dog SOD1 expressing cells. Transduced 






Figure 7 Summary of mitochondrial membrane potential (ΔΨm) (A: Confocal microscopy and 
B: Flow cytometry), ATP levels (C) and mitochondrial-derived superoxide ion levels (D) from 
virally-transduced cells expressing different SOD1 variants (wild-type dog (E40) SOD1 
(WTD), mutant dog (K40) SOD1 (Mut-D), wild-type horse (K40) SOD1 (WTH) and mutant 
horse (E40) SOD1 (Mut-H)) with appropriate vehicle and non-virally transduced control cells. 
Solid black line represents statistical differences of P < .05 and the dotted black line represents 





Supplementary Table 1: The volume of the mitochondrial networks in cells expressing 
different SOD1 variants, with vehicle and non-transduced controls were not significantly 
different from each other (p>0.05). The SOD1 variants included the wild-type dog SOD1 (E40) 
(WTD), mutant dog SOD1 (K40) (Mut-D), wild-type horse SOD1 (K40) (WTH) and mutant 
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Table 1: Primer Sequences 
 
SOD1 Genotyping in Different Perissodactyla Species and Horse Breeds  
Primer sequences used for SOD1 Exon 2 amplification (5’-3’): 
Equine SOD‐1 Exon 2 
Forward 1 
CACTTGCTCTCTCAAACTTGT Przewalski’s horse, 
Horse Breeds  
Equine SOD‐1 Exon 2 
Reverse 1 
TAGCAGTCATACTGACTTGACC Przewalski’s horse, 
Horse Breeds 
Equine SOD-1 Exon 2 
Forward 3 
GTCGTTCTGAAGGGATTCAT Onager, Chapman’s 
Zebra, Donkey, 
Malaysian Tapir 
Equine SOD-1 Exon 2 
Reverse 3 





Primer sequences used for mutagenesis (5’-3’): 
Horse SOD1 K40 Forward CTGTGGTCCCTTCGGATCTC 
Horse SOD1 K40 Reverse CTAGGACTCAGACCATGACAC 
 
qPCR Primers 
Primer sequences used for qPCR (all 5’ to 3’): 
Human GAPDH Forward  ATTCCACCCATGGCAAATTC 
Human GAPDH Reverse GGGATTTCCATTGATGACAAGC  
Human POLR2F Forward CCCGAAAGATCCCCATCAT 
Human POLR2F Reverse CACCCCCCAGTCTTCATAGC 
Human MPRIP Forward  ATCTCAGCCATCGAAGCCAT 
Human MPRIP Reverse  TGGCTCTTCTCCAGCTCCC 
Dog SOD1 Forward AAGTGGGCCTGTTGTGGTAT 
Dog SOD1 Reverse ATCCTTGCCAGCAGTCACAT 
Horse SOD1 Forward  ACCAAAGGCGATCACGGATT 
Horse SOD1 Reverse ATCAGCAGTCACATTGCCCA 
Human SOD1 Forward ATGGACCAGTGAAGGTGTGG 
Human SOD1 Reverse CTTTGGCCCACCGTGTTTTC 
 
  
Figure 1: Exon 2 fragment of SOD1 sequencing in 7 different horse breeds, 
centred around the 40th codon (red lines), showing the conservation of the lysine 





Figure 2: The volume of the mitochondrial networks in cells expressing different 
SOD1 variants, with vehicle and non-transduced controls were not significantly 
different from each other (p>0.05). The SOD1 variants included the wild-type dog 
SOD1 (E40) (WTD), mutant dog SOD1 (K40) (Mut-D), wild-type horse SOD1 (K40) 




Figure 3: Relative expression of dog SOD1 (WTD (E40) and Mut-D (K40)) and horse 
SOD1 (WTH (K40) and Mut-H (E40)) mRNA in virally transduced SHSY5Y cells, 
normalised to GADPH, MPRIP and POLR2F expression identified with specific 
primers to horse SOD1. The relative expression of WTH SOD1 and Mut-H SOD1 
were comparable to one another (p>0.05) mirroring the protein expression results. 
Negligible expression of horse SOD1 was seen in control, vehicle, WTD- and Mut-D-
expressing cells. Data is expressed as the mean + standard deviation from experimental 
replicates (n=3). Different letters indicate statistically significant differences between 









































































a a a a
b b
